Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04677855




Registration number
NCT04677855
Ethics application status
Date submitted
14/12/2020
Date registered
21/12/2020

Titles & IDs
Public title
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Scientific title
A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Secondary ID [1] 0 0
PCUR101-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - PCUR-101
Treatment: Drugs - Dutasteride 0.5 mg
Treatment: Drugs - Abiraterone and Prednisone

Experimental: PCUR-101 Dose Escalation - PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase

Experimental: PCUR-101 Dose Expansion Cohort 1 - PCUR-101 dosed orally once per day in 28 day cycles

Experimental: PCUR-101 Dose Expansion Cohort 2 - PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles

Experimental: PCUR-101 Dose Expansion Cohort 3 - PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles


Treatment: Drugs: PCUR-101
50 mg capsules

Treatment: Drugs: Dutasteride 0.5 mg
0.5 mg capsules

Treatment: Drugs: Abiraterone and Prednisone
500 mg tablets Abiraterone with 5 mg Prednisone Tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Occurrence of Dose Limiting Toxicity
Timepoint [1] 0 0
over the first 28 days of dosing
Secondary outcome [1] 0 0
Determination of pharmacokinetic parameters - Tmax
Timepoint [1] 0 0
over the first 28 days of dosing
Secondary outcome [2] 0 0
Determination of pharmacokinetic parameters - Cmax
Timepoint [2] 0 0
over the first 28 days of dosing
Secondary outcome [3] 0 0
Determination of pharmacokinetic parameters - T1/2
Timepoint [3] 0 0
over the first 28 days of dosing
Secondary outcome [4] 0 0
Preliminary Evidence of efficacy/anti tumor activity - PSA levels
Timepoint [4] 0 0
through study completion, average of 12 months
Secondary outcome [5] 0 0
Preliminary Evidence of efficacy/anti tumor activity - RECIST
Timepoint [5] 0 0
through study completion, average of 12 months

Eligibility
Key inclusion criteria
* Histologically confirmed diagnosis of prostate cancer
* Demonstrates metastatic CRPC
* Castrate level of serum testosterone at screening
* Adequate hematologic, renal, and hepatic function
* ECOG status =1
* Life expectancy of at least 3 months
* No more than one prior course of cytotoxic chemotherapy
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histology
* Visceral metastasis excluding lymph nodes
* Use of opiate analgesics for prostate cancer pain or non-cancer pain
* other investigational agents or concurrent anticancer therapy other than standard androgen deprivation therapy within 4 weeks
* History of bleeding disorder
* History of seizure disorder
* Concomitant use of warfarin
* Prior exposure to PCUR-101
* History of myocardial infarction, arterial thrombotic events, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia
* Received wide-field external beam radiation therapy within 4 weeks
* Moderate to severe neuropathy

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/03/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/11/2023
Sample size
Target
Accrual to date
Final
7
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
St. George Private Hospital - Kogarah
Recruitment hospital [2] 0 0
Southern Oncology Clinical Research - Bedford Park
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Michigan
Country [2] 0 0
United States of America
State/province [2] 0 0
Nebraska

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pellficure Pharmaceuticals, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04677855